Back to Search
Start Over
Genome-scale CRISPR-Cas9 knockout screening in gastrointestinal stromal tumor with Imatinib resistance.
- Source :
-
Molecular Cancer . 8/13/2018, Vol. 17 Issue 1, pN.PAG-N.PAG. 1p. 1 Chart, 2 Graphs. - Publication Year :
- 2018
-
Abstract
- Genome-scale CRISPR-Cas9 Knockout Screening was applied to investigate novel targets in imatinib-resistant gastrointestinal stromal tumor (GIST). 20 genes and 2 miRNAs have been selected by total reads of sgRNA and sgRNA diversity, which has been further validated in imatinib-resistant GIST cells by CCK8 and qPCR analysis. Our study has finally revealed 9 genes (DBP, NR3C1, TCF12, TP53, ZNF12, SOCS6, ZFP36, ACYP1, and DRD1) involved in imatinib-resistant GIST-T1 cells. TP53 and SOCS6 may be the most promising candidate genes for imatinib-resistance due to the possible signaling pathway, such as apoptosis pathway and Wnt signaling pathway, JAK-STAT signaling pathway. It is necessary to perform more studies to discover novel targets in imatinib-resistant GIST, including DBP, NR3C1, TCF12, ZNF12, ZFP36, ACYP1 and DRD1. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14764598
- Volume :
- 17
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Molecular Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 131227800
- Full Text :
- https://doi.org/10.1186/s12943-018-0865-2